236 related articles for article (PubMed ID: 32791263)
1. Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study.
Tian J; Yan S; Wang H; Zhang Y; Zheng Y; Wu H; Li X; Gao Z; Ai Y; Gou X; Zhang L; He L; Lian F; Liu B; Tong X
Pharmacol Res; 2020 Nov; 161():105127. PubMed ID: 32791263
[TBL] [Abstract][Full Text] [Related]
2. Timely treatment and higher compliance to traditional Chinese medicine: New influencing factors for reducing severe COVID-19 based on retrospective cohorts in 2020 and 2021.
Zhang Y; Liu Y; Li M; Feng S; Li X; Gao Z; Yang Y; Tong X
Pharmacol Res; 2022 Apr; 178():106174. PubMed ID: 35288309
[TBL] [Abstract][Full Text] [Related]
3. Add-on effect of Chinese herbal medicine in the treatment of mild to moderate COVID-19: A systematic review and meta-analysis.
Du X; Shi L; Cao W; Zuo B; Zhou A
PLoS One; 2021; 16(8):e0256429. PubMed ID: 34415962
[TBL] [Abstract][Full Text] [Related]
4. Chinese herbal medicine reduces mortality in patients with severe and critical Coronavirus disease 2019: a retrospective cohort study.
Chen G; Su W; Yang J; Luo D; Xia P; Jia W; Li X; Wang C; Lang S; Meng Q; Zhang Y; Ke Y; Fan A; Yang S; Zheng Y; Fan X; Qiao J; Lian F; Wei L; Tong X
Front Med; 2020 Dec; 14(6):752-759. PubMed ID: 32926320
[TBL] [Abstract][Full Text] [Related]
5. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
6. Clinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient cases.
Shu Z; Zhou Y; Chang K; Liu J; Min X; Zhang Q; Sun J; Xiong Y; Zou Q; Zheng Q; Ji J; Poon J; Liu B; Zhou X; Li X
Front Med; 2020 Dec; 14(6):760-775. PubMed ID: 32926319
[TBL] [Abstract][Full Text] [Related]
7. Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan, China: a retrospective, single-center study with propensity score matching.
Wang Y; Liu Y; Lv Q; Zheng D; Zhou L; Ouyang W; Ding B; Zou X; Yan F; Liu B; Chen J; Liu T; Fu C; Fang Q; Wang Y; Li F; Chen A; Lundborg CS; Guo J; Wen Z; Zhang Z
Phytomedicine; 2021 May; 85():153404. PubMed ID: 33637412
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.
Zeng C; Yuan Z; Pan X; Zhang J; Zhu J; Zhou F; Shan Z; Yuan Y; Ye R; Cheng J
Trials; 2020 Dec; 21(1):1029. PubMed ID: 33357239
[TBL] [Abstract][Full Text] [Related]
9. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
[TBL] [Abstract][Full Text] [Related]
10. [Epidemiological characteristics of COVID-19 in Wuchang district of Wuhan].
Chen YL; Wang H; Zhou YN; Lu ZH; Peng M; Sun F; Huang YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Oct; 41(10):1616-1622. PubMed ID: 33297617
[No Abstract] [Full Text] [Related]
11. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study.
Cen Y; Chen X; Shen Y; Zhang XH; Lei Y; Xu C; Jiang WR; Xu HT; Chen Y; Zhu J; Zhang LL; Liu YH
Clin Microbiol Infect; 2020 Sep; 26(9):1242-1247. PubMed ID: 32526275
[TBL] [Abstract][Full Text] [Related]
12. Add-On Chinese Medicine for Coronavirus Disease 2019 (ACCORD): A Retrospective Cohort Study of Hospital Registries.
Shu Z; Chang K; Zhou Y; Peng C; Li X; Cai W; Wei L; Zheng Q; Tian H; Xia J; Yang K; Wang N; Liu J; Min X; Yan D; Sun J; Wu H; Li X; Zheng Y; Yu Z; Lu X; Yang Y; Jia T; Ji J; Zou Q; Wang Y; Xiao M; Zhang Q; Xiong Y; Sun F; Zhu Q; Jiang X; Wang G; Tang SC; Zhang J; Li X; Zhang N; Zhang B; Tong X; Liu B; Zhou X; Chan KW; Li X
Am J Chin Med; 2021; 49(3):543-575. PubMed ID: 33683189
[TBL] [Abstract][Full Text] [Related]
13. Traditional Chinese Medicine Decoctions Significantly Reduce the Mortality in Severe and Critically Ill Patients with COVID-19: A Retrospective Cohort Study.
Sun QG; An XD; Xie P; Jiang B; Tian JX; Yang Q; Li XY; Luo M; Liu P; Zhao SH; Duan LY; Lang SP; Fan A; Luo PC; Lian FM; Huang XD; Tong XL
Am J Chin Med; 2021; 49(5):1063-1092. PubMed ID: 34107858
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of coronavirus disease 2019 in Gansu province, China.
Yue H; Bai X; Wang J; Yu Q; Liu W; Pu J; Wang X; Hu J; Xu D; Li X; Kang N; Li L; Lu W; Feng T; Ding L; Li X; Qi X;
Ann Palliat Med; 2020 Jul; 9(4):1404-1412. PubMed ID: 32692208
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for developing severe COVID-19 in China: an analysis of disease surveillance data.
Geng MJ; Wang LP; Ren X; Yu JX; Chang ZR; Zheng CJ; An ZJ; Li Y; Yang XK; Zhao HT; Li ZJ; He GX; Feng ZJ
Infect Dis Poverty; 2021 Apr; 10(1):48. PubMed ID: 33845915
[TBL] [Abstract][Full Text] [Related]
16. Traditional Chinese Medicine JingYinGuBiao Formula Therapy Improves the Negative Conversion Rate of SARS-CoV2 in Patients with Mild COVID-19.
Chen B; Geng P; Shen J; Liangpunsakul S; Lyu H; Zhang J; Yang Y; Zhang L; Xu Y; Dong C; Wang Y; Xue Y; Zhang W; Liu H; Li M; Gao Y
Int J Biol Sci; 2022; 18(15):5641-5652. PubMed ID: 36263182
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial.
Shi N; Guo L; Liu B; Bian Y; Chen R; Chen S; Chen Y; Chen Y; Cong X; Dong G; Guo J; Hu L; Jiang J; Leng L; Li B; Li D; Li H; Li J; Li L; Liu J; Lu C; Lv W; Miao Q; Qi W; Shi Z; Shi J; Shi H; Tian Y; Wang B; Wang G; Wang J; Wang W; Xian Y; Xie X; Xiong Y; Xu C; Xu M; Yan B; Yang J; Zhang L; Zhou Z; Zhu H; Huang L
Phytomedicine; 2021 Jan; 81():153367. PubMed ID: 33260064
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Traditional Chinese Medicine (TCM) Officially Recommended in China for COVID-19 Using Ontology-Based Side-Effect Prediction Framework (OSPF) and Deep Learning.
Wang Z; Li L; Song M; Yan J; Shi J; Yao Y
J Ethnopharmacol; 2021 May; 272():113957. PubMed ID: 33631276
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of prescription and medication rules of traditional Chinese medicine in the treatment of the coronavirus disease 2019 based on traditional Chinese medicine inheritance support platform].
Liu J; Li D; Mei J; Wu L; Chen F; Liu Y; Lang X; Yuan G; Zhao Y
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 May; 34(5):454-458. PubMed ID: 35728843
[TBL] [Abstract][Full Text] [Related]
20. The Effects of Traditional Chinese Medicine as an Auxiliary Treatment for COVID-19: A Systematic Review and Meta-Analysis.
Zhou LP; Wang J; Xie RH; Pakhale S; Krewski D; Cameron DW; Wen SW
J Altern Complement Med; 2021 Mar; 27(3):225-237. PubMed ID: 33252246
[No Abstract] [Full Text] [Related]
[Next] [New Search]
